MoonLake locks in commercial manufacturing with Vetter, faces penalties if orders fall short

Filed June 1, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

• high

  MoonLake signed a commercial supply agreement with Vetter to manufacture sonelokimab, transitioning from development to commercial-scale production and signaling preparation for potential product launch.

  Item 1.01 verify on EDGAR →
• high

  Company committed to minimum purchase quantities and must pay Vetter for lost revenue if orders fall short, creating financial obligations regardless of actual product demand or commercial success.

  Item 1.01 verify on EDGAR →
• high

  Manufacturing capacity is capped at a Maximum Quantity that cannot be increased without Vetter's consent, potentially limiting MoonLake's ability to scale production if commercial demand exceeds expectations.

  Item 1.01 verify on EDGAR →